Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. CEL-SCI Corporation
  6. News
  7. Summary
       US1508375086

CEL-SCI CORPORATION
Delayed Nyse  -  04:00:00 2018-12-20 pm EST
2.740 USD   -0.36%
05/23Cel Sci Corp : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly Prolonged Overall Survival in Head and Neck Cancer-Phase 3 Data Presented at ESTRO 2023
AQ
05/15Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
BU
SummaryChartsNewsRatingsCalendarCompanyFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about CEL-SCI CORPORATION
05/16Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
AQ
05/15Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
BU
05/15CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikin..
CI
05/12Cel-sci : Fiscal Q2 Earnings Snapshot
AQ
05/12CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
BU
05/12CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
04/27CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of..
BU
04/20CEL-SCI to Pursue Canada's Conditional Approval Pathway for Multikine in the Treatment ..
AQ
04/19CEL-SCI to Pursue Canada's Conditional Approval Pathway for Multikine in the Treatment ..
BU
03/09CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Extension
AQ
03/08CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Extension
BU
03/08CEL-SCI Corporation Reports New Data from Its Pivotal Phase 3 Study
CI
03/06CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
AQ
03/03CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
BU
02/15CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
BU
More most relevant news
All news about CEL-SCI CORPORATION
05/23Cel Sci Corp : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
AQ
05/15Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
BU
05/15CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikin..
CI
05/12Cel-sci : Fiscal Q2 Earnings Snapshot
AQ
05/12CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
BU
05/12CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
05/02Cel Sci Corp : Other Events (form 8-K)
AQ
05/01Cel Sci Corp : Entry into a Material Definitive Agreement, Other Events, Financial Stateme..
AQ
04/27CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of..
BU
More news
News in other languages on CEL-SCI CORPORATION
05/15CEL-SCI Corporation annonce les derniers résultats de son étude pivot de phase 3 sur Mu..
05/12CEL-SCI Corporation annonce ses résultats pour le deuxième trimestre et le semestre clo..
03/08CEL-SCI Corporation présente de nouvelles données issues de son étude pivot de phase 3
02/14CEL-SCI Corporation annonce ses résultats pour le premier trimestre clos le 31 décembre..
2022CEL-SCI Corporation annonce ses résultats pour l'exercice complet clos le 30 septembre ..
2022L'auditeur de CEL-SCI Corporation met en doute la pérennité de l'entreprise.
2022Cel-Sci rapporte des données positives de l'étude de phase 3 sur le traitement néoadjuv..
2022Cel-Sci déclare que les résultats positifs de l'essai de phase 3 du médicament contre l..
2022CEL-SCI Corporation annonce les résultats de la phase 3 de Multikine® pour le cancer de..
2022CEL-SCI Corporation annonce ses résultats pour le troisième trimestre et les neuf mois ..
More news
Analyst Recommendations on CEL-SCI CORPORATION
2022EF Hutton Cuts Price Target on Cel-Sci to $16 From $17, Maintains Buy Rating
MT
2022EF Hutton Initiates Cel-Sci With Buy Rating, $17 Price Target
MT
2022EF Hutton Initiates Cel-Sci at Buy with $17 Price Target
MT
More recommendations
Press releases
05/23Cel Sci Corp : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
AQ
05/15Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
BU
05/12Cel-sci : Fiscal Q2 Earnings Snapshot
AQ
05/12CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
BU
More press releases
Upcoming event on CEL-SCI CORPORATION
08/15/23Q3 2023 Earnings Release (Projected)
Upcoming sector events
07/25/23SAMSUNG BIOLOGICS CO. : Q2 2023 Earnings Release (Projected)
07/25/23BIOGEN INC. : Q2 2023 Earnings Release (Projected)
07/26/23BIOMARIN PHARMACEUTICAL INC. : Q2 2023 Earnings Release (Projected)
08/16/23CSL LIMITED : Q4 2023 Earnings Release
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Biopharmaceuticals
Stock markets for all
100% Free Registration
fermer